Tectonic Therapeutic (TECX) Income from Continuing Operations (2017 - 2026)
Tectonic Therapeutic (TECX) posted quarterly Income from Continuing Operations of 53803000.0 for Q1 2026, down 236.16% year-over-year from 39513468.32 in Q1 2025, and down 179.85% quarter-over-quarter from 19226000.0 in Q4 2025.
Powered by 
Analysis
Tectonic Therapeutic (TECX) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Tectonic Therapeutic (TECX) has reported Income from Continuing Operations for 10 consecutive years, with 53803000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 236.16% year-over-year to 53803000.0; the TTM figure through Mar 2026 stood at 112048000.0 (down 99.14% YoY), while the FY2025 annual figure was 74151000.0, down 33.65% from the prior year.
- Income from Continuing Operations fell to 53803000.0 in Q1 2026 per TECX's latest filing, from 19226000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 9275000.0 in Q4 2023 and bottomed at 53803000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 20516000.0 across 5 years, with a median of 19035000.0 in 2025.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations surged 64.08% — and 2026, when it plunged 236.16%.
- Tectonic Therapeutic's Income from Continuing Operations stood at 25818000.0 in 2022, then soared by 64.08% to 9275000.0 in 2023, then dropped by 6.46% to 9874000.0 in 2024, then plunged by 94.71% to 19226000.0 in 2025, then plunged by 179.85% to 53803000.0 in 2026.
- Business Quant data shows TECX's Income from Continuing Operations at 53803000.0 in Q1 2026, 19226000.0 in Q4 2025, and 19035000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Tectonic Therapeutic | 569.49 Mn | 569.49 Mn | - | -22.29 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -22.29 Mn |
| Mar 31, 2026 | -25.13 Mn |
| Dec 31, 2025 | -2.91 Mn |
| Sep 30, 2025 | -19.04 Mn |
| Jun 30, 2025 | -19.98 Mn |
| Mar 31, 2025 | -15.87 Mn |
| Dec 31, 2024 | -197,000.00 |
| Sep 30, 2024 | -17.72 Mn |
| Jun 30, 2024 | -12.67 Mn |
| Mar 31, 2024 | -12.74 Mn |
| Dec 31, 2023 | -9.28 Mn |
| Sep 30, 2023 | -10.05 Mn |
| Jun 30, 2023 | -10.45 Mn |
| Mar 31, 2023 | -24.97 Mn |
| Dec 31, 2022 | -25.01 Mn |
| Sep 30, 2022 | -22.87 Mn |
| Jun 30, 2022 | -28.06 Mn |
| Mar 31, 2022 | -29.83 Mn |
| Dec 31, 2021 | -28.21 Mn |
| Sep 30, 2021 | -32.62 Mn |